BIV201 continuous infusion

Drug identity checked against registry records

Also recorded as terlipressin diacetate

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study for Evaluation of BIV201 to Reduce Ascites and Complications in Patients With Cirrhosis and Refractory AscitesNCT04112199BIVIPhase 2Terminated2023-05-08Actual

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.